PSA: What Your Number Changes About Your Treatment

What PSA Actually Measures

PSA is a serine protease produced almost exclusively by prostate epithelial cells. Its biological job is to liquefy semen. A small amount leaks into the bloodstream, and that measurable fraction is what clinicians use to monitor prostate health and guide treatment decisions.

The test itself is straightforward: a standard blood draw, no fasting required. But interpretation is anything but simple. PSA rises with prostate cancer, yes. It also rises with benign prostatic hyperplasia (BPH), prostatitis, recent ejaculation, vigorous cycling, and certain medications. A single elevated reading does not equal cancer. The 2018 USPSTF recommendation statement emphasized that PSA-based screening reduces prostate cancer mortality but carries risks of overdiagnosis and overtreatment, which is why shared decision-making between patient and provider became the standard for men aged 55 to 69 [1].

PSA exists in two forms in blood: bound to proteins and free (unbound). The ratio between them matters. A free-to-total PSA ratio below 10% increases the probability that an elevation is cancer-related, while a ratio above 25% suggests BPH as the more likely cause [2]. This distinction prevents unnecessary biopsies.

Normal PSA Ranges by Age

There is no universal "normal." The reference range shifts upward as men age because the prostate grows over time. The commonly cited threshold of 4.0 ng/mL is a population average, not a personalized cutoff.

Age-adjusted reference ranges based on large cohort data published in JAMA break down roughly as follows [3]:

• Men aged 40 to 49: 0 to 2.5 ng/mL
• Men aged 50 to 59: 0 to 3.5 ng/mL
• Men aged 60 to 69: 0 to 4.5 ng/mL
• Men aged 70 to 79: 0 to 6.5 ng/mL

These ranges are not treatment thresholds. They are descriptive. A 42-year-old man with a PSA of 2.4 ng/mL sits at the upper boundary of his age group and deserves closer follow-up than a 72-year-old with the same number. Context determines action.

The Endocrine Society's 2018 clinical practice guideline for testosterone therapy reinforces that baseline PSA must be obtained before initiating TRT, with follow-up measurements at 3 to 6 months and then annually [4]. Dr. Shalender Bhasin, the guideline's lead author, stated: "Men with a baseline PSA above 4 ng/mL should be referred for urological evaluation before testosterone therapy is initiated" [4].

How PSA Shapes Testosterone Therapy Decisions

Testosterone replacement therapy (TRT) has a direct, measurable effect on PSA. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies involving 790 men aged 65 and older, showed that one year of testosterone gel treatment increased median PSA by 0.11 ng/mL compared to placebo [5]. That increase is modest. But it is consistent, and it matters clinically because it can push borderline values across a decision threshold.

The Endocrine Society guideline draws clear lines [4]:

1. Before starting TRT: obtain a baseline PSA. If PSA exceeds 4 ng/mL, refer to urology first.
2. At 3 to 6 months: recheck PSA. If PSA has risen by more than 1.4 ng/mL per year (annualized), refer to urology.
3. Annually thereafter: continued monitoring. Persistent upward trends warrant investigation regardless of the absolute number.

A man who begins TRT with a PSA of 1.2 ng/mL and rises to 1.5 ng/mL at six months is on a normal trajectory. The same man rising from 1.2 to 3.0 ng/mL in six months has a velocity of 3.6 ng/mL per year. That velocity is a red flag requiring a urology referral, even though 3.0 ng/mL is technically within the "normal" population range.

PSA Velocity: Why the Trend Outweighs the Snapshot

A single PSA value is a photograph. Velocity is the video. PSA velocity measures the rate of change over time, typically requiring at least three measurements spanning 18 to 24 months for reliable calculation.

The concept gained clinical weight after a 2004 study published in the Journal of the National Cancer Institute demonstrated that a PSA velocity greater than 0.35 ng/mL per year, measured years before diagnosis, was associated with a significantly higher risk of lethal prostate cancer [6]. That finding shifted clinical practice from relying on single-point thresholds toward trend analysis.

For men on TRT, the Endocrine Society uses a more conservative velocity threshold: 1.4 ng/mL per year [4]. The reasoning is practical. Testosterone raises PSA in nearly all men who start therapy, so the threshold accounts for the expected treatment-related increase while still catching suspicious acceleration.

PSA doubling time is a related metric used primarily after a prostate cancer diagnosis. A doubling time shorter than three months suggests aggressive disease. For screening and TRT monitoring purposes, velocity is the more relevant measure. Track it.

When a Rising PSA Forces a Treatment Change

Rising PSA during TRT does not automatically mean stopping testosterone. It means investigating. The clinical algorithm follows a sequence, not a single switch.

First, confirm the elevation. Repeat the PSA test after 4 to 6 weeks, ensuring the patient avoided ejaculation for 48 hours and vigorous prostate-area exercise for one week before the draw. Transient elevations from these causes are common and clinically meaningless.

Second, calculate velocity. If confirmed velocity exceeds 1.4 ng/mL per year or the absolute PSA crosses 4 ng/mL, refer to urology for evaluation, which may include digital rectal examination, MRI, or biopsy [4].

Third, consider dose adjustment. A 2017 meta-analysis in Medicine examining 26 randomized controlled trials with 4,538 participants found that testosterone therapy increased PSA by a weighted mean of 0.10 ng/mL compared to placebo, with intramuscular injections producing a larger increase than transdermal formulations [7]. Switching from injections to a patch or gel may moderate the PSA rise while preserving therapeutic benefit.

Fourth, if biopsy is negative and velocity stabilizes, TRT may continue with closer monitoring (every 3 months instead of annually). The decision is collaborative. Dr. Abraham Morgentaler, a urologist at Harvard Medical School, wrote in the Journal of Urology: "There is no compelling evidence that testosterone therapy increases the risk of prostate cancer, but vigilant monitoring of PSA remains the standard of care" [8].

5-Alpha Reductase Inhibitors and the PSA Correction Factor

Finasteride (5 mg) and dutasteride (0.5 mg) are commonly prescribed for BPH and male pattern hair loss. Both drugs suppress PSA by approximately 50% within 6 to 12 months of use. This pharmacologic reduction creates a measurement problem.

The Prostate Cancer Prevention Trial (PCPT), a landmark study enrolling 18,882 men, demonstrated that finasteride reduced the overall risk of prostate cancer by 24.8% over seven years [9]. But it also showed that PSA values during finasteride use must be doubled to approximate the "true" underlying PSA. A man on finasteride with a measured PSA of 2.0 ng/mL has an estimated corrected value of 4.0 ng/mL.

This correction is not optional. Failing to apply it can mask a rising PSA and delay diagnosis. The FDA label for finasteride explicitly instructs clinicians to multiply measured PSA by two when assessing prostate cancer risk in men taking the drug [10].

For men on both TRT and a 5-alpha reductase inhibitor, PSA monitoring becomes a two-step process: measure, double the value, then assess velocity and absolute level against the standard thresholds. The combination is common, particularly in men over 50 receiving testosterone for hypogonadism and finasteride for BPH.

How to Lower PSA Without Stopping Therapy

Not every PSA elevation requires discontinuing treatment. Several evidence-supported strategies can reduce PSA or slow its rise.

Treat infection. Subclinical prostatitis is a frequent and underrecognized cause of PSA elevation. A course of antibiotics (typically fluoroquinolones or trimethoprim-sulfamethoxazole for 4 to 6 weeks) can drop PSA by 30% or more if bacterial prostatitis is present. Urine culture and expressed prostatic secretion analysis guide this decision.

Address BPH pharmacologically. Alpha-blockers such as tamsulosin reduce lower urinary tract symptoms but have minimal effect on PSA. The 5-alpha reductase inhibitors described above will lower PSA by about half, which is both a therapeutic effect and a monitoring complication.

Modify the testosterone delivery method. As the 2017 meta-analysis indicated, transdermal testosterone produces a smaller PSA increase than intramuscular injections [7]. Switching formulations is a reasonable first step when PSA velocity is mildly concerning but below the referral threshold.

Optimize body composition. A 2014 study in BJU International found an inverse relationship between obesity and PSA, partly because hemodilution in higher blood volumes lowers measured PSA concentrations [11]. This does not mean weight loss "raises" PSA in a dangerous way. It means that obese men may have falsely low PSA readings, and weight normalization reveals the true baseline.

Avoid confounders before blood draws. Ejaculation within 48 hours, prostate massage, cycling over 30 minutes, and urinary tract instrumentation all transiently raise PSA. Standardizing pre-test conditions eliminates these artifacts.

USPSTF and Endocrine Society Screening Guidelines

Two guidelines govern PSA use in the populations most relevant to HealthRX patients.

The 2018 USPSTF recommendation (Grade C for ages 55 to 69) advises individualized, shared decision-making about PSA screening [1]. It explicitly recommends against routine screening in men 70 and older (Grade D). The task force grounded its position in two large trials: the European Randomized Study of Screening for Prostate Cancer (ERSPC), which showed a 20% relative reduction in prostate cancer mortality at 16 years with screening [12], and the U.S. PLCO trial, which showed no mortality benefit but was limited by high contamination rates in the control arm.

The Endocrine Society 2018 guideline layers TRT-specific rules on top of general screening [4]:

• Baseline PSA before any testosterone prescription
• PSA recheck at 3 to 6 months
• Annual PSA thereafter
• Urology referral if PSA exceeds 4 ng/mL, if velocity exceeds 1.4 ng/mL per year, or if a palpable prostate abnormality is found on digital rectal exam

The AACE 2024 guidelines on male hypogonadism echoed these thresholds and added that men with a family history of prostate cancer should begin PSA monitoring at age 40 rather than 50 [13].

These guidelines do not conflict. They address different clinical questions. The USPSTF asks whether to screen asymptomatic men at all. The Endocrine Society asks how to monitor men who are already receiving a drug that affects PSA. Both frameworks apply simultaneously to a man on TRT.

PSA Density and Free PSA: Refining the Gray Zone

When PSA falls between 4 and 10 ng/mL (the so-called "gray zone"), two additional metrics help distinguish BPH from cancer and guide whether a biopsy is necessary.

PSA density divides the total PSA by prostate volume measured on transrectal ultrasound or MRI. A density above 0.15 ng/mL per cubic centimeter raises suspicion for cancer [14]. A 60-year-old man with a PSA of 6 ng/mL and a 60 cc prostate has a density of 0.10, which is reassuring. The same PSA in a 30 cc prostate yields a density of 0.20, warranting biopsy consideration.

Free PSA percentage provides a second filter. As noted above, cancer cells release more bound PSA, so a low free percentage (<10%) is concerning. A meta-analysis in JAMA concluded that using a free PSA cutoff of 25% in the 4 to 10 ng/mL range could avoid 20% of unnecessary biopsies while detecting 95% of cancers [2].

For men on TRT with gray-zone PSA, both metrics add precision to the referral decision. Neither replaces biopsy when clinical suspicion is high, but they reduce the number of men subjected to an invasive procedure without adequate justification.

What a Very Low PSA Tells Your Clinician

Most clinical attention focuses on high PSA. Low values carry information too. A PSA below 0.5 ng/mL in a man not taking finasteride or dutasteride generally indicates low prostate volume and minimal BPH. In the context of prostate cancer follow-up after radical prostatectomy, an undetectable PSA (<0.1 ng/mL) is the target, and any measurable rise above that threshold defines biochemical recurrence.

For men considering TRT, a very low baseline PSA provides reassurance. The TTrials data showed that men starting from a lower baseline had smaller absolute PSA increases [5]. A baseline of 0.4 ng/mL rising to 0.6 ng/mL over a year represents normal hormonal stimulation and does not require intervention.

A PSA below 1.0 ng/mL at age 60 is associated with a very low lifetime risk of clinically significant prostate cancer, according to data from the Malmo Preventive Project published in BMJ [15]. This finding supports the concept of risk-stratified screening intervals: men with low baseline PSA may safely extend screening intervals to every 2 to 4 years rather than annually.